3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Carcinosarcoma
2
Brain Neoplasms
2
Wilms Tumor
1
Stage I Mixed Cell Type Kidney Wilms Tumor
1
Rhabdomyosarcoma, Embryonal
1
Rhabdomyosarcoma, Alveolar
1
Rhabdomyosarcoma
1
Recurrence
1
Prostatic Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pancreatic Intraductal Neoplasms
1
Ovarian Neoplasms
1
Non functioning pancreatic endocrine tumor
1
Neuroendocrine Tumors
1
Lung Neoplasms
1
Locally Advanced Cervical Adenocarcinoma
1
Liposarcoma
1
Histiocytoma, Malignant Fibrous
1
Fallopian Tube Neoplasms
1
Colorectal Neoplasms
1
Burkitt Lymphoma
1
Barrett Esophagus
1
Anus Neoplasms
1
Anal Canal Carcinoma
1
Adenoma, Islet Cell
1
Interventions
Dexamethasone
28
Rituximab
16
pomalidomide
13
Gemcitabine
12
Lenalidomide
11
Cisplatin
11
Bortezomib
11
Paclitaxel
10
Cyclophosphamide
8
Carboplatin
8
carfilzomib
7
selinexor
5
daratumumab
5
Drug Therapy
5
Doxorubicin
5
Cytarabine
5
ibrutinib
4
Vincristine
4
Temozolomide
4
Prednisone
4
Docetaxel
4
Calcium Dobesilate
4
Bevacizumab
4
Aspirin
4
tisagenlecleucel
3
Cetuximab
3
Bendamustine Hydrochloride
3
venetoclax
2
ofatumumab
2
galiximab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Recurrence
×
X-Rays
×
Clear all
NCT02636634
2016-04-11
CV-METANEC
Assistance Publique - Hôpitaux de Paris
Phase 3
Completed
90 enrolled